KASINGER JAMES R. 4
4 · CRISPR Therapeutics AG · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
CRISPR (CRSP) General Counsel James R. Kasinger Sells 3,450 Shares
What Happened
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), had 6,875 restricted stock units (RSUs) vest/convert into common shares on 2026-03-14. Following that settlement, he sold 3,450 shares in an open-market transaction on 2026-03-16 at $48.26 per share, generating $166,497. The Form 4 also records the 3/14 conversion/settlement of 6,875 derivative/RSU units into shares.
Key Details
- Transaction dates and amounts:
- 2026-03-14: Exercise/conversion (M) / settlement of 6,875 RSUs into common shares.
- 2026-03-16: Open-market sale (S) of 3,450 shares @ $48.26 = $166,497.
- Shares owned after transaction: Not specified in the filing.
- Notable footnotes:
- F2/F4: These were RSUs (each RSU = one contingent right to a share). The award was granted 3/14/2025 for 27,500 shares with quarterly vesting; 6,875 vested 3/14/2026.
- F3: The 3,450-share sale was required by the company’s RSU Settlement Policy to cover tax withholding and was not a discretionary trade.
- F1: Some shares remain subject to a lock-up agreement with underwriters of the issuer’s convertible notes offering.
- Filing: Form 4 filed 2026-03-17; no late filing is indicated in the report.
Context
The filing shows a routine RSU vest-and-settle event followed by a mandatory sell-to-cover for taxes. The M code reflects conversion/exercise of a derivative instrument (here, the RSU settlement). Because the sale was mandated for tax withholding and some shares remain locked up, this transaction should not be read as a discretionary vote of confidence or concern by the insider.
Insider Transaction Report
- Exercise/Conversion
Common Shares
[F1][F2]2026-03-14+6,875→ 94,690 total - Sale
Common Shares
[F3]2026-03-16$48.26/sh−3,450$166,497→ 91,240 total - Exercise/Conversion
Restricted Stock Units
[F2][F1][F4]2026-03-14−6,875→ 20,625 total→ Common Shares (6,875 underlying)
Footnotes (4)
- [F1]These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
- [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F4]This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.